Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231897 | 0.85 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL28947571 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL29184186 | 0.84 | KDR (0.76) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL18993402 | 0.83 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL20990144 | 0.83 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL7988912 | 0.83 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037590 | 0.83 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL10415452 | 0.83 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL30686047 | 0.83 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL16592903 | 0.83 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2GRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885SMN1; SMN2 3410/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885SMN1; SMN2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.